Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · IEX Real-Time Price · USD
14.89
+0.21 (1.43%)
At close: Apr 26, 2024, 4:00 PM
14.81
-0.08 (-0.54%)
After-hours: Apr 26, 2024, 7:37 PM EDT
Catalyst Pharmaceuticals Employees
Catalyst Pharmaceuticals had 167 employees on December 31, 2023. The number of employees increased by 85 or 103.66% compared to the previous year.
Employees
167
Change (1Y)
85
Growth (1Y)
103.66%
Revenue / Employee
$2,384,455
Profits / Employee
$427,605
Market Cap
1.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 167 | 85 | 103.66% |
Dec 31, 2022 | 82 | 6 | 7.89% |
Dec 31, 2021 | 76 | 2 | 2.70% |
Dec 31, 2020 | 74 | -2 | -2.63% |
Dec 31, 2019 | 76 | 25 | 49.02% |
Dec 31, 2018 | 51 | 30 | 142.86% |
Dec 31, 2017 | 21 | 3 | 16.67% |
Dec 31, 2016 | 18 | -5 | -21.74% |
Dec 31, 2015 | 23 | 11 | 91.67% |
Dec 31, 2014 | 12 | 5 | 71.43% |
Dec 31, 2013 | 7 | 1 | 16.67% |
Dec 31, 2012 | 6 | 0 | - |
Dec 31, 2011 | 6 | 0 | - |
Dec 31, 2010 | 6 | 0 | - |
Dec 31, 2009 | 6 | -1 | -14.29% |
Dec 31, 2008 | 7 | 0 | - |
Dec 31, 2007 | 7 | 2 | 40.00% |
Dec 31, 2006 | 5 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
NeoGenomics | 2,100 |
Ginkgo Bioworks Holdings | 1,218 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Beam Therapeutics | 507 |
Recursion Pharmaceuticals | 500 |
Agios Pharmaceuticals | 386 |
Harmony Biosciences Holdings | 246 |
CPRX News
- 2 days ago - Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May - GlobeNewsWire
- 5 days ago - Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 - GlobeNewsWire
- 22 days ago - Jim Cramer recommends five small-cap health-care stocks - CNBC
- 4 weeks ago - Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day - GlobeNewsWire
- 4 weeks ago - Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium - GlobeNewsWire
- 6 weeks ago - Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States - GlobeNewsWire
- 6 weeks ago - Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 7 weeks ago - Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference - GlobeNewsWire